These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10716066)

  • 41. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition.
    Kantarci K; Lowe VJ; Lesnick TG; Tosakulwong N; Bailey KR; Fields JA; Shuster LT; Zuk SM; Senjem ML; Mielke MM; Gleason C; Jack CR; Rocca WA; Miller VM
    J Alzheimers Dis; 2016 May; 53(2):547-56. PubMed ID: 27163830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis.
    Stehman-Breen C; Anderson G; Gibson D; Kausz AT; Ott S
    Kidney Int; 2003 Jul; 64(1):290-4. PubMed ID: 12787421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and pharmacodynamics of a novel estrogen delta8-estrone in postmenopausal women and men.
    Bhavnani BR; Cecutti A; Gerulath A
    J Steroid Biochem Mol Biol; 1998 Oct; 67(2):119-31. PubMed ID: 9877212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50.
    Reginster JY; Albert A; Deroisy R; Colette J; Vrijens B; Blacker C; Brion N; Caulin F; Mayolle C; Regnard A; Scholler R; Franchimont P
    Maturitas; 1997 Jun; 27(2):179-86. PubMed ID: 9255753
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of orally administered estradiol valerate. Results of a single-dose cross-over bioequivalence study in postmenopausal women.
    Zimmermann H; Koytchev R; Mayer O; Börner A; Mellinger U; Breitbarth H
    Arzneimittelforschung; 1998 Sep; 48(9):941-7. PubMed ID: 9793623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic studies on low dose estradiol 17 beta administered orally to postmenopausal women.
    Sipinen S; Lähteenmäki P; Luukkainen T
    Acta Obstet Gynecol Scand; 1980; 59(2):149-53. PubMed ID: 6773291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women.
    Baracat E; Haidar M; Castelo A; Tufik S; de Lima GR; Vieira JG; Peloso U; Casoy J
    Maturitas; 1996 Apr; 23(3):285-91. PubMed ID: 8794422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
    Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J
    Menopause; 2006; 13(5):840-5. PubMed ID: 16894332
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system.
    Müller P; Botta L; Ezzet F
    Eur J Clin Pharmacol; 1996; 51(3-4):327-30. PubMed ID: 9010707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women.
    Lippert TH; Seeger H; Mueck AO
    Horm Metab Res; 1998 Sep; 30(9):598-600. PubMed ID: 9808331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and pharmacodynamics of oral and transdermal 17β estradiol in girls with Turner syndrome.
    Taboada M; Santen R; Lima J; Hossain J; Singh R; Klein KO; Mauras N
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3502-10. PubMed ID: 21880799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
    Davis SR; Stuckey BG; Norman RJ; Papalia MA; Drillich A; Bell RJ
    Menopause; 2008; 15(6):1065-9. PubMed ID: 18806686
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Half-life of estradiol in postmenopausal women.
    Ginsburg ES; Gao X; Shea BF; Barbieri RL
    Gynecol Obstet Invest; 1998; 45(1):45-8. PubMed ID: 9473164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
    Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
    Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?
    Brosnan JF; Sheppard BL; Norris LA
    Thromb Haemost; 2007 Apr; 97(4):558-65. PubMed ID: 17393018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss.
    Palacios S
    Climacteric; 2002 Jun; 5 Suppl 2():32-9. PubMed ID: 12482109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spotlight on estradiol-intranasal in the management of menopause.
    Dooley M; Spencer CM; Ormrod D
    Treat Endocrinol; 2002; 1(3):191-4. PubMed ID: 15799211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A switch from oral (2 mg/day) to transdermal (50 microg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency.
    Janssen YJ; Helmerhorst F; Frölich M; Roelfsema F
    J Clin Endocrinol Metab; 2000 Jan; 85(1):464-7. PubMed ID: 10634425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.